Glax­o­SmithK­line and Vir sub­mit Covid-19 mAb for emer­gency au­tho­riza­tion

As the US con­tin­ues to mon­i­tor the im­pact of vari­ants on au­tho­rized mon­o­clon­al an­ti­bod­ies (mAbs) and shake up which mAbs are dis­trib­uted where, Glax­o­SmithK­line and Vir Biotech­nol­o­gy said Fri­day that they’re seek­ing an emer­gency use au­tho­riza­tion for their own mAb.

The com­pa­nies are sub­mit­ting an ap­pli­ca­tion for their mAb, known as VIR-7831, as a treat­ment for adults and ado­les­cents (12 years and old­er) with mild-to-mod­er­ate Covid-19 who are at risk for pro­gres­sion to hos­pi­tal­iza­tion or death.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.